Skip to main content
SpringerLink
Log in

Risk of cholangiocarcinoma with incretin-based drugs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. T2DM = type 2 diabetes mellitus

  2. DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1

References

  1. Abrahami D, et al. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study. BMJ 363: [8 pages], 5 Dec 2018. Available from: URL: https://doi.org/10.1136/bmj.k4880.

  2. Adler AI. Incretins and cancer of the bile duct in type 2 diabetes. BMJ : [2 pages], 6 Dec 2018. Available from: URL: https://doi.org/10.1136/bmj.k5155.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of cholangiocarcinoma with incretin-based drugs. Reactions Weekly 1732, 14 (2018). https://doi.org/10.1007/s40278-018-55470-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-55470-8

Search

Navigation